New Clinical Data Highlights Onera Health’s Patch-Based Home Polysomnography Solution at SLEEP 2025
4.6.2025 15:00:00 EEST | Business Wire | Press release
Onera Health, a leader in transforming remote sleep diagnostics and monitoring, has today announced that its patient-applied patch-based home Polysomnography Solution will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2025 conference. The MedTech company will showcase this innovative solution at booth #1145 during the largest annual conference, which brings together leading experts and innovators in the field of sleep medicine. Furthermore, Onera Health will host a symposium on "Advancing Access to PSG" on Monday, June 9.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604390799/en/
A female patient is sleeping while undergoing a sleep study with Onera Health's home Polysomnography solution.
The 39th annual meeting of the Associated Professional Sleep Societies (APSS) will present the latest clinical data and insights that promise to reshape the landscape of sleep medicine. This year's conference will take place from June 8 to 11, 2025, in Seattle, Washington.
“We are excited to see our Patch-based Type II Polysomnography System highlighted in four different presentations and to be an integral part of the evolving field of sleep medicine by advancing access to the gold standard of PSG sleep testing,” states Ruben de Francisco, Founder and CEO of Onera Health.
The clinical utility of the Onera home PSG system will be presented in four poster presentations. Details of the presentations are as follows:
Title: Assessment of Disease Burden in PAP-Intolerant OSA Patients Using Home Polysomnography: A Pilot Study
Authors: Heiser C et al.
Poster Board Number: #219
Poster Presentation Date and Time: June 9, 2025, 10:00 - 11:45 am
Abstract ID: 661
Title: Signal Quality and Recording Characteristics of Patient-Applied Home Polysomnography: A Real-World Analysis Across US and European Settings
Authors: Dimitrov T et al.
Poster Board Number: #543
Poster Presentation Date and Time: June 10, 2025, 11:00 - 11:45 am
Abstract ID: 1666
Title: Validation of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #319
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 677
Title: Patient Perception of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #320
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 678
Additional presentations by experts from leading institutions will feature validation results, insights from real-world implementation, and the clinical implications of home PSG testing during a symposium titled "Expanding Access, Enhancing Outcomes: The Future of Sleep Diagnostics with Home Polysomnography," which will be hosted by Onera Health on June 9.
“Home polysomnography addresses significant challenges, including the shortage of in-laboratory beds, technicians, and sleep physicians. This shortage has led to escalating costs and an increasing unmet clinical demand, with many patients suffering from sleep disorders remaining undiagnosed. This symposium aims to provide valuable insights into how hPSG can enhance patient care pathways and is already beginning to reshape the landscape of sleep healthcare by broadening access to gold standard PSG testing. I am confident that it will foster engaging discussions with esteemed panelists regarding the emerging opportunities for remote sleep diagnostics and care,” explains Ruben de Francisco.
Attendees can anticipate the following presentations:
- David P. White, MD, part-time Professor of Medicine at Harvard Medical School – "The Perfect Storm: Why Sleep Medicine Needs to Transform Now"
- Thomas Penzel, PhD, Charité University Hospital Berlin – "Home Polysomnography Comes of Age: Validation Study Results"
- Anupamjeet Kaur Sekhon, MD, Kaiser Permanente Fontana Medical Center– "From Lab to Home: Implementing Home Sleep Testing at Scale"
About Onera Health
Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the United States. For further information, please visit onerahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604390799/en/
Contacts
Swea Ann Hagenhoff
E: media@onerahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 16:30:00 EEST | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country. The funding will advance Project Obsidian, the world's first commercial superhot geothermal power plant, in Central Oregon. It will support analysis of the drilling, stimulation, and flow results of the first two wells to optimize a third well at the Obsidian site. The three-well configuration is targeting average reservoir temperatures of over 300°C and is designed to demonstrate more than 25 megawatts of gross electric power capacity. The DOE funding will also enable Qu
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 16:00:00 EEST | Press release
Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and their families access care, adopt healthier habits, and improve long-term oral health outcomes. “At Colgate-Palmolive, we believe oral health and healthier, brighter futures are inextricably link
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 15:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 15:30:00 EEST | Press release
Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Today’s leading family offices are building long-term strategies underpinned by three key themes: capital, capability and continuity. They are investing with confidence -- becoming more institutional in how they invest, more sophisticated in how they manage risk, and more intentional in how they prepare for the future. Families also are prioritizing leadership succession and generational transition with new urgency. Key takeaways include: Strong Performance in the Face of Rising Uncertainty: Despite shifting macroe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom